Experience with the combined drug (bromhexine + guaifenesin + salbutamol) in patients with acute bronchitis and bronchial obstruction syndrome. Case report

Acute cough is one of the leading reasons for adult patients seeking primary medical care. The most common cause of acute cough is acute bronchitis. Modern domestic and international clinical guidelines agree that acute bronchitis is a self-limiting disease, and the basis of treatment remains symptomatic therapy and informing the patient about the natural course of the disease. The therapeutic strategy is usually aimed at symptomatic relief of cough, reducing the subjective severity of the disease and preventing the unjustified use of antibacterial drugs. The pathogenesis of cough in acute bronchitis is due to a combination of inflammatory infiltration of the bronchial mucosa, impaired mucociliary clearance, increased production of bronchial secretions and the development of transient hypersensitivity of cough receptors. Some patients have temporary bronchial hyperreactivity accompanied by reversible bronchial obstruction, which explains the occurrence of wheezing and episodes of expiratory dyspnea. The multifactorial nature of the pathogenesis of acute bronchitis determines the interest in combination therapy, which includes drug combinations and simultaneously affects various links in the pathogenesis of acute bronchitis. A fixed combination of bromhexine, guaifenesin, and salbutamol provides a pathogenetically sound treatment option for productive cough in acute bronchitis due to a combination of mucolytic, expectorant, and bronchodilating effects. This article presents a retrospective analysis of 2 clinical cases of the use of Bromhexcomb® and Bromhexcomb Expectorant® (in the form of tablets and syrup) containing fixed doses of bromhexine hydrochloride, guaifenesin, and salbutamol sulfate in patients with acute bronchitis and airway obstruction is presented. The drugs have been shown to be highly effective in the treatment of cough. The drugs demonstrated good tolerability, and no adverse reactions were reported. Thus, the combined drug Bromgecomb® and Bromgecomb expectorant® represent a effective and pathogenetically sound treatment option for productive cough in patients with acute bronchitis with bronchial obstructive syndrome. The presence of two dosage forms (tablets and syrup) makes Bromgecomb one of the drugs of choice among other combined drugs.